demonstrated that assembled and non-secreted 375W fibrinogen was accumulated in the dilated ER and aggregated variant fibrinogen was seen as regularly structured fibular materials, which was similar to the fingerprint-like pattern observed at inclusion bodies in patients' hepatocytes affected with HERSD.
Introduction
Fibrinogen is a 340-kDa plasma glycoprotein synthesized in hepatocytes and secreted into the blood, and plays crucial roles in blood clotting, wound healing, inflammation, angiogenesis, and cellular and matrix interactions [1] . Circulated fibrinogen consists of two copies of three polypeptide chains, A, B, and , linked by an extensive network of 29 intra-and inter-chain disulfide bonds [2, 3] . After synthesis in hepatocytes, individual polypeptide chains are translocated into the rough endoplasmic reticulum (ER) and initially A- and B- intermediates are formed with disulfide bonds and subsequently connected with B-or A-chain, leading to the formation of a half molecule (A-B-) [4, 5] . Two half molecules are assembled into a hexameric molecule with disulfide bonds, folded, and glycosylated in the ER and Golgi apparatus 4 before secretion. Aberrantly conformed fibrinogen or unassembled individual polypeptide chains are retained within the ER and degraded by the proteasome pathway as the ER-associated protein degradation (ERAD) system [6, 7] .
Hypofibrinogenemia or afibrinogenemia, defined as reduced or negligible levels of fibrinogen in plasma, can be hereditary. Genetic abnormalities in patients with these diseases have been found in all three genes and identified as missense, nonsense, or frameshift mutations; splice-site abnormalities; or large deletions, as listed in the fibrinogen variant database [updated on 26/01/2012, http://site.geht.org/site/Pratiques-Professionnelles/Base-de-donnees-Fibrinogene/Base-d e-donnees/Base-de-donnees-des-variants-du-Fibrinogene_40_.html]. Some patients with only four variant types of hypofibrinogenemia, substitution of G284R [8] , T314P [9] , and R375W mutation [10] [11] [12] [13] [14] , and deletion of G346-Q350 [15] (all numbered as mature protein without signal peptide) have been reported to show onset of liver disease in so-called hepatic ER storage disease (HERSD) [16] or fibrinogen storage disease, being in the same category as genetic deficiency of -1-antitrypsin (A1AT) (G342K, Z-mutation) [17] .
We have already established eight variant fibrinogen-synthesizing CHO cells, all showing reduced secretion of variant fibrinogen into the media [18, 19] . In addition, these cells showed elevated levels of cytoplasmic fibrinogen. Namely, some single In this study, to analyze the variant fibrinogen-producing Chinese hamster ovary (CHO) cells causing HERSD, we established CHO cells synthesizing γ375W, γ375G, or γ375E fibrinogen, and compared the synthesis of fibrinogen and morphological characteristics because the variant fibrinogen, R375W, was found in HERSD patients with heterozygous hypofibrinogenemia [10] [11] [12] [13] [14] and fibrinogen Osaka V, R375G, was reported as heterozygous dysfibrinogenemia [20] . Immunofluorescence using anti-fibrinogen antibody showed that only 375W, not γ375G or γ375E fibrinogen-synthesizing CHO cells, formed cytoplasmic inclusion bodies. To characterize the inclusion bodies we observed the 375W fibrinogen-synthesizing CHO cells by confocal laser scanning microscopy (CLSM) and transmission electron microscopy. for γ375E according to the instruction manuals. To confirm the insertion of each mutation, the complete -chain cDNAs of the plasmids were sequenced as described previously [21] .
Materials and methods

Construction of mutant expression vectors and recombinant protein expression.
The resultant expression vectors, γ375W, γ375G, γ375E, and  chain expression vector (375R) were transfected into CHO cells that expressed normal human fibrinogen A and B chains (AB-CHO cells) using the standard calcium-phosphate co-precipitation method, and stable transfectants were selected using both G418 (GIBCO BRL, Rockville, MD, USA) and histidinol (Aldrich Chemical, Milwaukee, WI, USA) and the cell lines were designated as γ375W-, γ375G-, γ375E-, andγ375R-CHO cells, respectively. Nine to twelve colonies from fibrinogen-synthesizing CHO cells were selected at random, expanded, and examined for fibrinogen synthesis. The cells 7 were cultured in Dulbecco's modified Eagle's medium Ham nutrient mixture F12, supplemented as described (DMEM-F12 medium).
Enzyme-linked immunosorbent assay (ELISA) and immunoblot analysis
Fibrinogen concentrations in culture media or cell lysates were determined by enzyme-linked immunosorbent assay (ELISA) as described previously [21] . Culture Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis were performed as described previously [21] . Briefly, immunoblots were developed with a rabbit anti-human fibrinogen antibody (Dako, Carpinteria, CA, USA) and the reacting species were visualized using horseradish peroxidase conjugate-goat anti-rabbit IgG antibody (Medical and Biological Laboratories, Nagoya, Japan) and enhanced chemiluminescence (ECL) detection reagent (Amersham Pharmacia Biotech, Buckinghamshire, UK). Blots were exposed on 
Hyperfilm-ECL (Amersham Pharmacia Biotech).
Statistical analysis
The statistical significance of differences between the normal control and variant fibrinogen-producing cells was determined using unpaired t tests. A difference was considered significant when p<0.05.
Immunofluorescence staining
For immunofluorescence microscopy, the cells grown to 80% confluent on cover-glass 
Transmission electron microscopy
For transmission electron microscopy, the cells grown to 80% confluence on cover-glass in a 60-mm culture dish were fixed with 2.5% glutaraldehyde in 0.1M phosphate buffer (pH 7.4) at 4 °C overnight, followed with 1% osmium tetroxide in 0.1M phosphate buffer at 4 °C 30 min. After dehydration, cells were embedded in epoxy resin. Ultrathin sections (90 nm) were placed in 200 mesh copper grids and stained with uranyl acetate (10 min) and lead citrate (5 min) and coated with a thin carbon layer. The specimens were observed on JEM -1230 (JEOL, Tokyo, Japan) and images were recorded at 30000 × with an 80 kV accelerating voltage. ER diameters were measured on a 267%
enlargement from an image of 30 000× magnification.
Results
Synthesis and secretion of recombinant variant fibrinogens in CHO cells
The variant fibrinogen or normal fibrinogen was expressed in CHO cells and 9 to 12 fibrinogen-synthesizing cell lines each were selected as described in Materials and Fig. 1-B) . Moreover, the concentrations in the culture media of γ375G-and γ375E-CHO cells were significantly elevated compared with that in normal cells, 1.8-and 2.1-fold, respectively. On the other hand, the concentration in the culture media of γ375W-CHO cells was significantly lower than that in the normal cells (0.32-fold) ( Fig.   1-A) . The medium/cell lysate fibrinogen ratio of γ375W-CHO cells was markedly lower (0.09 ± 0.02) than that of the normal cells (0.94 ± 0.10) and other two mutant cells (γ375G-CHO cells; 1.10 ± 0.25, γ375E-CHO cells; 1.00 ± 0.53, respectively ( Fig. 1-C) .
To observe the assembly of intact fibrinogen and/or synthesis of a mutant -chain,
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SDS-PAGE and immunoblotting analysis were performed under non-reducing or reducing conditions. Under non-reducing conditions, intact fibrinogen was observed in cell lysates of all three fibrinogen variants, including γ375W and normal fibrinogen-expressing cell lines (Fig. 2-A) . Under reducing conditions, not only Aα-and Bβ-chain but also γ-chain were observed in cell lysates of three variant fibrinogen and normal fibrinogen-expressing cell lines (Fig. 2-B) . Interestingly, the amount of the γ-chain band of γ375W-CHO cells was higher than that of other fibrinogen-expressing cell lines.
Fibrinogen staining for variant fibrinogen-synthesizing CHO cells
To analyze the localization of variant fibrinogen in established CHO cells, a direct immunofluorescence test with FITC labeled anti-fibrinogen antibody was performed as described in Materials and Methods. Original CHO cells (Fig. 3A) did not produce fibrinogen and were used as a negative control. Normal fibrinogen-synthesizing γ375R-CHO cells were stained in a perinuclear network pattern (Fig.3B ) and used as a positive control. Variant fibrinogen-synthesizing cell lines, γ375G-CHO cells (Fig. 3C) and γ375E-CHO cells (Fig. 3D) were stained in a similar pattern to γ375R-CHO cells.
Surprisingly, γ375W-CHO cells (Fig. 3-E, F) showed three staining patterns, namely scattered large-granular bodies (abbreviated as 'g'), fibrous forms of two subpolar sites of nucleus (abbreviated as 'f'), and a perinuclear network (abbreviated as 'n'). On day 3 after subculture, the frequency of each staining pattern ('g', 'f' and 'n') was 32.6%, 22.4%, and 44.9%, respectively. However, CHO cells having two aberrant patterns in a single cell, namely 'g' + 'f' pattern, were seen rarely (<0.5%).
Analyses of aberrant structure of γ375W fibrinogen-synthesizing CHO cells.
To analyze where γ375W-fibrinogen was accumulated and from where the aberrant structure of γ375W fibrinogen-synthesizing CHO cells was derived, observation using confocal laser scanning microscopy (CLSM) was performed for stained cells with anti-calnexin antibody (calnexin is an ER-membrane marker) (red) and anti-fibrinogen antibody (green), as described in Materials and Methods. As shown by confocal microscopy, ER-membrane protein was localized typically in a perinuclear network pattern. In addition, the aberrant structure of scattered large-granular bodies (Fig. 4 C,   D ) and fibrous forms (Fig. 4 C, E) in γ375W-CHO cells co-localized with calnexin, resulting in a yellow merged signal (Fig. 4 C-E) .
To ascertain the accumulation of γ375W-fibrinogen in aberrant structured ER, we observed the ER in CHO cells by transmission electron microscopy. Images are shown in Fig. 5 . ER width of γ375R-CHO cells as a normal control (Fig. 5A, D) were 64.0 ± 13.6 nm (n = 14). On the other hand, ER of γ375W-CHO cells with scattered large 13 granular bodies (Fig. 5B, E) showed enlarged vacuoles with diameters of 760.4 ± 125.5 nm (n = 6). For γ375W-CHO cells with fibrous forms (Fig. 5C, F) , the width of the ER was expanded slightly, 176.6 ± 34.7 nm (n = 22) and, moreover, the ER lumen was filled with regularly structured fibular materials. These appeared to have a fingerprint-like pattern, as shown in hepatocytic inclusion bodies of HERSD patients by transmission electron microscopy [10] [11] [12] [13] [14] .
Changes of aberrant structure of γ375W fibrinogen-synthesizing CHO cells and subcloning.
To analyze whether two types of aberrant cytoplasmic inclusion in γ375W-CHO cells, large granular bodies ('g') and fibrous forms ('f'), are the same clone and derived from the normal type as a perinuclear network ('n') or a transition of each other, we stained CHO cells by immunofluorescence from day 1 to day 7 after subculturing ( Fig. 6 ). On day 1, the frequency of each staining pattern ('g', 'f', and 'n') was 23.5, 10.1, and 66.4%, 'n' pattern cells decreased and 'g' and 'f' pattern cells increased according to the culture period, and finally, on day 7 'g', 'f', and 'n' pattern cells were 47.7, 50.0, and 2.3%, respectively. In addition to the frequency change of the staining pattern, the intracellular fibrils elongated each day (Fig. 6 ). In addition, double aberrant patterns of 'g' and 'f' were seen in CHO cells on day 3 (Fig. 6C) . 
Discussion
To examine the assembly and/or secretion of variant fibrinogens substituted at R375 residues375G, 375E, and 375W were expressed in CHO cells as stable transfectants.
All these cell lines synthesized a mutant -chain, and assembled it into fibrinogen in the cells. Moreover, the former two variants secreted a large amount of fibrinogen into the culture media but the latter secreted a markedly small amount. Variant fibrinogen Osaka V, R375G, was reported as heterozygous dysfibrinogenemia; namely, the plasma fibrinogen concentration determined by the thrombin time method was 0.9 g/L and that determined by an immunological method was 2.5 g/L [20] . On the other hand, HERSD-induced variant known as fibrinogen Aguadilla; R375W, was reported as heterozygous hypofibrinogenemia; namely, the plasma fibrinogen concentration determined by the thrombin time method and immunological method was 0.6 g/L by both [10] . Another four identical variant fibrinogens also reported lower levels of plasma fibrinogen and were diagnosed as hypofibrinogenemia [11] [12] [13] [14] . Overall,
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considering the excretion pattern of 375W we conclude that our recombinant fibrinogen-producing system using CHO cells gives results similar to patients with hypofibrinogenemia.
To analyze the accumulation and localization of variant fibrinogen in the cytoplasm of γR375 variant CHO cells, immunofluorescence staining was performed. Surprisingly, only γ375W-CHO cells showed two types of cytoplasmic inclusion bodies, scattered large granular bodies and fibrous forms. Observation by confocal microscopy demonstrated that these aberrant structures were colocalized with ER-membrane protein.
Further observation by transmission electron microscopy indicated dilatation of the ER by large granular bodies and filling with regularly structured fibular materials within the ER on a fibrous structure. These results demonstrated that assembled and non-secreted 375W fibrinogen was accumulated in the dilated ER and aggregated variant fibrinogen was seen as regularly structured fibular material, being similar to the fingerprint-like pattern observed at inclusion bodies in patients' hepatocytes affected with HERSD [10] [11] [12] [13] [14] . In addition to R375W mutation, G284R [8] , T314P [9] , and deletion of G346-Q350 [15] , all mutations residing in the globular D domain, have been reported as HERSD with hypofibrinogenemia, and all also demonstrated the presence of hepatocellular cytoplasmic inclusion bodies filled with anti-fibrinogen antibody-reacting materials and were also observed as tubular materials with a 16 fingerprint-like pattern by electron microscopy [8, 9, 15] . ER accumulation of variant protein inducing liver cirrhosis (HERSD) was originally reported in a deficiency (homozygotes) of A1AT (G342K, Z-mutation) [17] . In general, it is well known that improperly folded proteins and aggregated proteins are often retained and/or degraded within the ER [22] . In addition to A1AT and fibrinogen, variants of other acute phase proteins (-1-antichymotrypsine, antiplasmin, C3, and C4) and defects of low-density lipoprotein (LDL) receptor have been shown to be retained within the ER [16] .
Kruse et al. demonstrated using a yeast expression system that variant D domain of 375W was cleared from the ER via ER-associated protein degradation, and when the ER was saturated, aggregated variant D domain was accumulated within the ER and sent to vacuoles for degradation via the autophagy pathway [23] . In brief, the report suggested the possibility that HERSD associated with variant fibrinogenemia might be caused by decreasing function of the autophagic pathway. Moreover, molecular mechanisms of A1AT homozygous Z mutation causing hepatocyte injury have been studied extensively and showed increased ER retention as a conformational disease [24] , activation of ER-specific stress responses [25] , up-regulated mitochondrial autophagy [26] , or mitochondrial injury and apoptosis [27] . Our γ375W-CHO cells indicated cytoplasmic aberrant inclusion bodies with large granular or fibrous forms and this suggested that variant fibrinogen was retained and aggregated within the dilated ER. In In conclusion, γ375W-CHO cells indicated that the assembly of variant fibrinogen was normal but secretion was markedly reduced and these observations suggest that hypofibrinogenemia is induced in heterozygous γR375W patients. In addition, cytoplasmic aberrant inclusion bodies in γ375W-CHO cells, especially fibrous forms, were comparable to the hepatocellular inclusion bodies observed in hypofibrinogenemia patients associated with HERSD. We hope that immunofluorescence staining of CHO cells and/or liver cells accumulating variant fibrinogens will be used as a screening procedure for possible HERSD before onset (elevated liver enzyme in serum).
Moreover, these cells are useful for to analyzing the molecular mechanisms of ER storage disease and conformational disease causing inclusion bodies to accumulate unfolded protein within the cells or matrix. 
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